Gilead Sciences, Inc. today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company's ...

RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences ... interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the ...

Arcus’s dependence on the collaboration with Gilead for the successful development and commercialization of its optioned molecules; and the inherent uncertainty associated with pharmaceutical ...

Under the Gilead and Arcus collaboration agreement ... and the inherent uncertainty associated with pharmaceutical product development and clinical trials. Risks and uncertainties facing Arcus ...

The International Research Centre on Artificial Intelligence (IRCAI), an organization under the auspices of UNESCO, in collaboration with Amazon Web Services, Inc. (AWS), today announced the selection ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report). The ...

Nov 6 (Reuters) - Gilead Sciences (GILD.O), opens new tab reported third-quarter financial results that handily beat Wall ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) today. The company’s ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other pharma ...

Gilead’s HIV sector, populated by dominant HIV treatment Biktarvy and PrEP Descovy, contributed $5.1 billion to the company’s total quarterly sales haul of $7.5 billion, reflecting growth of 7 ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...